Objective — to evaluate the effectiveness of the hepatotropic complex Lesil® for the prevention of the development of drug‑induced liver damage in patients receiving anti‑Helicobacter therapy (AHT). Materials and methods. Observation involved the main (I) and control (II) groups of 40 people in each. Patients with gastroduodenal diseases were included in the study if Helicobacter pylori (H. pylori) infection was first detected. A 14‑day course of 4‑component AHT was administered: pantoprazole, amoxicillin, clarithromycin, colloidal bismuth subcitrate. The main group additionally received Lesil® (Propharma Plant LLC, Ukraine) in a dose of 2 capsules a day for 6 weeks. Patients’ satisfaction with therapy was assessed using a visual analog scale. Statistical processing of the obtained results was carried out using standard methods. Results. After the course of treatment, eradication of H. pylori was achieved in 76 subjects (95%). After the end of AHT in the I group, no changes in liver tests were registered, whereas in the II group, an increase in the activity of ALT and AST in 2.4 (p<0.05) and 2.9 times (p<0.01) was revealed, as well as an increase in the levels of γ‑glutamyltranspeptidase (p<0.01) and alkaline phosphatase (p<0.01), and increase in the fraction of direct bilirubin. Patients of the II group were less satisfied with the treatment: the indicators of the visual analog scale were 4.97±068, compared to the I group (8.43±1.21, p<0.05). Conclusions. Against the background of AHT (PPI in a standard dose, amoxicillin, clarithromycin, colloidal bismuth subcitrate) for 14 days, signs of drug‑induced liver damage were detected, which persisted for 4 weeks after the end of therapy. Hepatocomplex Lesil® is an effective means to prevent drug damage to the liver. This is confirmed by the absence of signs of cytolytic and cholestatic syndromes in the group of patients who received Lesil® 2 capsules per day for 6 weeks in addition to the AHT. Hepatocomplex Lesil® demonstrated safety and good tolerance by patients who were satisfied with AHT in combination with Lesil®.